Intercell: Difference between revisions

Revision as of 11:14, 10 June 2009

Revision as of 19:02, 25 July 2009

Line 31:

}}

'''Intercell AG''' is a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a [[spin-off]] of the Institute of Molecular Pathology of the [[University of Vienna]].{{Fact|date=August 2008}} It employs 240400 people in Austria, Scotland and the United States.

It has been listed on the [[Vienna Stock Exchange]] since [[February 28]], [[2005]]. In 2008, Intercell acquired [[Iomai]], a developer of needle-free vaccination technology, now operated as Intercell USA.<ref>

Line 74:

* [[Antigen]] identification program and [[adjuvant]] technologies.{{Fact|date=August 2008}}

== References ==

{{reflist}}

== External links ==

*[http://www.intercell.com/ Intercell Homepage]